High-quality APIs. Zero disruption.
Global reliability.
28–30 October 2025
Messe Frankfurt, GermanyOur Team at CPHI Frankfurt 2025
Deepak Sapra
CEO, Pharmaceutical Services & Active Ingredients
Nirav Shah
Vice President, and Head, API - North Asia
Karun Gaur
Vice President and Head, Strategic Projects API
Dr. A Kalyan Chakravarthy
Executive VP & Head – SEAMEA & B2B Formulations
Kalpesh
Vice President, and Head – EU Market, API & B2B Collaborations
E Sreedhar
Executive Vice President, API Regulatory Affairs
Gustavo Mayrink De Castro Marques
Vice President and Head, API Sales & Marketing, LATAM
Dr. NM Sekhar
Vice President, API R&D
R Lalitha Kumari
Global Head of API Product Management & Head of Sales - US & Canada
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
-
250+ APIs
-
8 Manufacturing sites
-
1970+ drug master files across global markets.
-
Over 325 ANDAs
-
Filed 4500+ patents globally, out of which 1125 have been granted.
-
Experience with complex APIs and formulations supporting early market entries.
-
Preferred pharma API supplier for pharma companies in more than 80 countries.
Sustainability
Sustainability is at the heart of our purpose. In FY2025, we served 756M+ patients, progressed to 60% carbon neutrality, and drew 68% of our power from renewables, all while staying water positive since FY2023.
We’re the only Indian pharma company to earn “A” scores in Climate Change, Water Security, and Supplier Engagement from CDP, and featured on the Dow Jones Sustainability World Index and S&P Global Sustainability Yearbook.
Our goals are clear:
- 100% renewable power by 2030
- Carbon neutrality (Scope 1 & 2) by 2030
- 1.5B patients served by 2030
We innovate with care, scale with purpose, and act with accountability to shape a healthier world.
What we achieved in the past year:
Our Achievement (awards)
10/07/2025
CDP Recognition
05/08/2025
Tentative Approval for Generic Lumateperone capsules
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
About CPHI Frankfurt 2025
This flagship global event brings together 2,400+ exhibitors, 62,000+ pharma professionals, and cutting-edge innovations across APIs, biopharma, contract services, packaging, machinery, and more. It’s where the world’s pharmaceutical leaders connect to unlock new opportunities, strengthen partnerships, and stay ahead in a rapidly shifting global market.
As part of this vibrant ecosystem, we’re excited to engage with peers, customers, and collaborators. We're here to create lasting value and help you if you're exploring dependable API partnerships, looking to scale your sourcing strategies, or seeking operational agility.
Let’s meet at CPHI Frankfurt. We’re ready to support your next phase of growth with reliable, agile, and future-ready API solutions.
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。
Let’s discuss API sourcing
Join us at Hall - 9.1 | Booth - B48